To hear about similar clinical trials, please enter your email below
Trial Title:
Prospective Multi-omics Observational Study of Gynecological Rare Pathological Tumors
NCT ID:
NCT05985941
Condition:
Rare Gynecological Tumors
Multi-omics Analysis
Conditions: Keywords:
Genomics
Transcriptome
proteomics
metabonomics
Pathological omics
Imaging omics
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
The goal of this observational study is to draw the characteristic maps of genomics,
transcriptome, proteomics, metabolomics, etc. in 600 patients with gynecological rare
pathological types of malignant tumors. Then it is planned to explore the molecular
mechanism and find some new targets for diagnosis and treatment, and design and establish
the database system of the above rare tumors.
Criteria for eligibility:
Study pop:
Patients with rare gynecological tumors who underwent surgery in three hospitals,
including Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine,
Sun Yat-sen Memorial Hospital affiliated to Sun Yat-sen University and the First
Affiliated Hospital of University of Science and Technology of China, were diagnosed as
clear cell carcinoma (ovary, uterus), neural small-cell carcinoma (ovary, uterus),
carcinosarcoma or sarcoma (ovary, uterus), cervical gastric adenocarcinoma, ovarian germ
cell tumor, ovarian sex cord stromal tumors, trophoblastic tumors, or perivascular
epithelioid cell tumors (PECOMA), among others.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- 1)Pathological diagnosis: clear cell carcinoma (ovary, uterus), nerve small-cell
carcinoma (ovary, uterus), carcinosarcoma or sarcoma (ovary, uterus), cervical
gastric adenocarcinoma, ovarian germ cell tumor, ovarian sex cord stromal tumor,
trophoblastic tumor, perivascular epithelioid cell tumor (PECOMA) and other rare
gynecological tumors; 2)Received pathological results from tumor surgery; 3)The
patient voluntarily participated in this research project with good compliance and
was able to complete the enrollment according to the experimental requirements;
4)Sign the informed consent form and consent to the collection and use of their
data, and consent to genomics, transcriptome and other tests.
Exclusion Criteria:
- 1)Patients with malignant tumors in other parts of the body; 2)Suffering from
uncontrollable neurological diseases, psychiatric diseases, or psychiatric
disorders; 3)Poor compliance and inability to cooperate and describe treatment
responders.
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
August 2023
Completion date:
May 2028
Lead sponsor:
Agency:
RenJi Hospital
Agency class:
Other
Source:
RenJi Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05985941
